PCAT18 and prostate carcinoma: Similar to the aforementioned lncRNAs, PCAT-18 can be detected in plasma, and its expression increases incrementally as prostate cancer progresses from localized to metastatic disease, suggesting that PCAT-18 is a potential biomarker for metastatic prostate cancer [38].